Glycogen synthase kinase-3β (GSK-3β) inhibition enhances dendritic cell-based cancer vaccine potency via suppression of interferon-γ-induced indoleamine 2,3-dioxygenase expression

Journal of Biological Chemistry

Volumn 290, Issue 19, 2015, Pages 12394-12402

  Noh, Kyung Tae ^a   Son, Kwang Hee ^b   Jung, In Duk ^b   Kang, Tae Heung ^b   Choi, Chang Hun ^a   Park, Yeong Min ^b  

^a Armed Forces Medical Research Institute   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBIOTICS; CELL PROLIFERATION; CELLS; CHEMICAL ACTIVATION; CYTOLOGY; ENZYME ACTIVITY; ENZYMES; GLYCOPROTEINS; LYMPHOCYTES; PROTEINS; TUMORS; VACCINES;

ANTI-TUMOR ACTIVITIES; CELL POLARIZATION; CELL SUPPRESSION; CYTOTOXIC T LYMPHOCYTES; GLYCOGEN SYNTHASE KINASE-3; IMMUNE TOLERANCES; INDOLEAMINE 2 ,3-DIOXYGENASE; PROTEIN KINASE C;

T-CELLS;

DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOGEN SYNTHASE KINASE 3BETA; INDOLEAMINE 2,3 DIOXYGENASE; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE C DELTA; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; CANCER VACCINE; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REGULATION; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION; THYMOMA; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIGEN PRESENTING CELL; C57BL MOUSE; CELL LINE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; METABOLISM; MIXED LYMPHOCYTE CULTURE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

MURINAE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; DENDRITIC CELLS; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84929167634     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.628578     Document Type: Article

References (26)

1. Mellor, A. L., and Munn, D. H. (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762-774
2. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B., and Palucka, K. (2000) Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811
3. Löb, S., Königsrainer, A., Rammensee, H. G., Opelz, G., and Terness, P. (2009) Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 9, 445-452
4. Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., Mellor, A. L., Munn, D. H., and Antonia, S. J. (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T-cell-mediated rejection. Int. J. Cancer 101, 151-155
5. Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., and Mellor, A. L. (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280-290
6. Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., and Van den Eynde, B. J. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269-1274
7. Zhang, Y., Wang, Y., Ogata, M., Hashimoto, S., Onai, N., and Matsushima, K. (2000) Development of dendritic cells in vitro from murine fetal liver-derived lineage phenotype-negative c-kit(+) hematopoietic progenitor cells. Blood 95, 138-146
8. Hayashi, T., Beck, L., Rossetto, C., Gong, X., Takikawa, O., Takabayashi, K., Broide, D. H., Carson, D. A., and Raz, E. (2004) Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114, 270-279
9. Takikawa, O., Habara-Ohkubo, A., and Yoshida, R. (1990) IFN-γ is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection. J. Immunol. 145, 1246-1250
10. Chon, S. Y., Hassanain, H. H., and Gupta, S. L. (1996) Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in in-terferon-γ-inducible expression of human indoleamine 2,3-dioxygenase gene. J. Biol. Chem. 271, 17247-17252
11. Ramsauer, K., Farlik, M., Zupkovitz, G., Seiser, C., Kröger, A., Hauser, H., and Decker, T. (2007) Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-γ-inducible gbp2 gene. Proc. Natl. Acad. Sci. U.S.A. 104, 2849-2854
12. Jeong, Y. I., Kim, S. W., Jung, I. D., Lee, J. S., Chang, J. H., Lee, C. M., Chun, S. H., Yoon, M. S., Kim, G. T., Ryu, S. W., Kim, J. S., Shin, Y. K., Lee, W. S., Shin, H. K., Lee, J. D., and Park, Y. M. (2009) Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cδ-STAT1 signaling pathway in interferon-γ-stimulated murine dendritic cells. J. Biol. Chem. 284, 3700-3708
13. Doble, B. W., and Woodgett, J. R. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186
14. Luo, J. (2009) Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy. Cancer Lett. 273, 194-200
15. Martin, M., Rehani, K., Jope, R. S., and Michalek, S. M. (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6, 777-784
16. Noh, K. T., Park, Y. M., Cho, S. G., and Choi, E. J. (2011) GSK-3β-induced ASK1 stabilization is crucial in LPS-induced endotoxin shock. Exp. Cell Res. 317, 1663-1668
17. Rodionova, E., Conzelmann, M., Maraskovsky, E., Hess, M., Kirsch, M., Giese, T., Ho, A. D., Zöller, M., Dreger, P., and Luft, T. (2007) GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood 109, 1584-1592
18. Beurel, E., and Jope, R. S. (2008) Differential regulation of STAT family members by glycogen synthase kinase-3. J. Biol. Chem. 283, 21934-21944
19. Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M. S., Jin, O., and Woodgett, J. R. (2000) Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 406, 86-90
20. Noh, K. T., Cho, S. G., and Choi, E. J. (2010) Knockdown of apoptosis signal-regulating kinase 1 modulates basal glycogen synthase kinase-3β kinase activity and regulates cell migration. FEBS Lett. 584, 4097-4101
21. Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., and Carbone, F. R. (1994) T-cell receptor antagonist peptides induce positive selection. Cell 76, 17-27
22. Lin, C. F., Tsai, C. C., Huang, W. C., Wang, C. Y., Tseng, H. C., Wang, Y., Kai, J. I., Wang, S. W., and Cheng, Y. L. (2008) IFN-γ synergizes with LPS to induce nitric oxide biosynthesis through glycogen synthase kinase-3-inhibited IL-10. J. Cell Biochem. 105, 746-755
23. Muller, A. J., and Prendergast, G. C. (2007) Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr. Cancer Drug Targets 7, 31-40
24. Munn, D. H., and Mellor, A. L. (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117, 1147-1154
25. Ferrantini, M., Capone, I., and Belardelli, F. (2008) Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev. 19, 93-107
26. Liu, Y. J. (2001) Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106, 259-262